P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
372 Indexminimum alveolar concentration (MAC), 114 ,
115t
lipid solubility,100f
minoxidil, 256
misoprostil, 296 –297
mivacurium, 46 –47, 90, 190–192
moclobemide, 277
molecular size, diffusion rate, 5
molecule–protein complex, 3
monoamine oxidase, 18 , 87–88
adrenaline metabolism, 203
adrenergic neurone blockade, 263
blood–brain barrier, 15
dopamine kinetics, 205
noradrenaline kinetics, 204
monoamine oxidase inhibitors, 276 –278
general anaesthesia, 277 –278
non-selective irreversible, 277
pethidine interactions, 144
selective reversible, 277
monobactams, 318
N-monomethyl-L-arginineseeL-NMMA
MOP (μreceptors), 137
morphine, 139
effects, 139 –141
keto-enol transformation, 45
kinetics, 141 –142
metabolism, 142
papaveretum, 142 –143
presentation, 139
uses, 139
motor nerves, unmyelinated, 175
mucosal protectors, 296
multi-compartment models, 68
clearance of drug, 73 –74
time constant, 74
volume of distribution, 72
muscle mass, elderly people, 23
muscle relaxants
blood–brain barrier crossing, 15
pharmacological/physiological interactions,
186t
physiology, 175
muscle relaxants, depolarizing, 177 ,
179 –184
tetanic stimulation, 178
see alsosuxamethonium
muscle relaxants, non-depolarizing,
184 –192
aminosteroids, 90
bis-benzylisoquinolinium, 46 –47, 90
classification, 184 –185
competitive inhibitions, 35
kinetics,190t
in labour, 17neostigmine use, 42
patterns of block,178f
properties,188t
single twitch stimulation, 177
structure,191f
tetanic stimulation, 178
train-of-four, 179
myalgia, suxamethonium-induced, 181
myopathy
atracurium-induced, 189
critical illness, 185 –186Na+/amino acid symport,3–4
Na+/H+ATPase proton pump, 294
Na+/K+AT Pase,3–4, 163
digoxin inhibition, 231 –233
nabilone, 291
nalbuphine, 149
nalidixic acid, 320 –321
nalorphine, 149
naloxone, 91 , 148
nausea, 282
domperidone use in children, 296
physiology, 282
see alsoantiemetics
neomycin, 319 –320
neonates, 22 –23
enzyme systems, 23
neostigmine, 42 , 194f, 195
netilmicin, 319 –320
neuromuscular block
monitoring, 177 –179
partial,177f, 180t
Phase I, 180
Phase II, 180
types,177f
neuromuscular junction
acetylcholine receptor
nicotinic, 25
occupancy, 38
antagonists, 35 –37
stimulation patterns, 177 –179
structure,176f
suxamethonium effects, 180
neurotransmitters
general anaesthetic effects at central
receptors,101t
see alsoacetylcholine (ACh); GABA; glycine;
NMDA receptor; noradrenaline
nicorandil, 251 –252
effects, 251 –252
kinetics, 252
mechanism of action, 251
presentation, 251
uses, 251